Clinical Trials Logo

Fever clinical trials

View clinical trials related to Fever.

Filter by:

NCT ID: NCT00873626 Completed - Fever Clinical Trials

Treatment's Duration of Acute Uncomplicated Pyelonephritis

DTP
Start date: June 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy of 5 days versus 10 days treatment duration in uncomplicated acute pyelonephritis. Acute pyelonephritis is a common disease and the treatment duration is not found on scientific evidence. If a short treatment is equal to standard duration, it will possible to shortening antibiotherapy with ecologic and economic advantage.

NCT ID: NCT00869713 Completed - Rift Valley Fever Clinical Trials

Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated

RVF
Start date: September 2009
Phase: Phase 2
Study type: Interventional

This study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults

NCT ID: NCT00845754 Completed - Pain Clinical Trials

Post-Operative Treatment With Ketorolac After Abdominal Myomectomy

Start date: September 1999
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if ketorolac, given after abdominal myomectomy, will decrease the frequency of post-oerative fevers as well as improve post-operative pain management.

NCT ID: NCT00842530 Completed - Dengue Fever Clinical Trials

Efficacy and Safety of Dengue Vaccine in Healthy Children

Start date: February 2009
Phase: Phase 2
Study type: Interventional

The primary objective of the study was to assess the efficacy of CYD dengue vaccine after three injections in preventing symptomatic virologically-confirmed dengue (VCD) cases, regardless of the severity, due to any of the four serotypes in children aged 4 to 11 years at the time of inclusion. Secondary objectives included to assess: - Vaccine efficacy against severe VCD cases - Vaccine efficacy against VCD cases following at least two injections with CYD dengue vaccine - Immune response to CYD dengue vaccine - Safety profile of CYD dengue vaccine. Safety assessments include solicited reactions within 7 or 14 days after each injection, unsolicited adverse events within 28 days after each injection, and serious adverse events during the study period. Other objectives included: - Vaccine efficacy against VCD cases following at least one injection with CYD dengue vaccine - Vaccine efficacy against VCD cases due to each serotype - Participants with clinical signs and symptoms for VCD

NCT ID: NCT00826085 Completed - Breast Cancer Clinical Trials

Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall

DIGNITY
Start date: February 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This is a research study to evaluate the effects of ThermoDox in combination with therapeutic heating of the chest wall in the treatment of recurrent regional breast cancer. The purpose of this study is to evaluate the bioequivalence of ThermoDox and measure efficacy in recurrent chest wall patients.

NCT ID: NCT00812422 Completed - Fever Clinical Trials

The Efficacy and Safety of Dexibuprofen Syrup

Start date: February 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the safety and efficacy of dexibuprofen syrup and ibuprofen syrup in patients with fever due to common cold.

NCT ID: NCT00809913 Completed - Clinical trials for Urinary Tract Infection

Febrile Urinary Tract Infection Randomized Short Treatment Trial

FUTIRST
Start date: December 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether a 7-day duration of antibiotic treatment of febrile urinary tract infection (FUTI) is non inferior to 14-day standard duration of treatment in unselected population presenting at primary care or emergency department.

NCT ID: NCT00800488 Completed - Fever Clinical Trials

Procalcitonin for Predicting Serious Bacterial Infection in Infants Less Than 3 Months

PRONOUR
Start date: October 2008
Phase: N/A
Study type: Observational

The primary objective is to study the value of serum procalcitonin as a predictive marker for severe bacterial infection in febrile infants. 2200 febrile infants aged less than 3 months will prospectively be included. All infants will have a measure of Procalcitonin concentrations. Comparison of the mean value of Procalcitonin concentration in infants with and without serious Bacterial infection. Evaluation of the area under the ROC for Procalcitonin concentration.

NCT ID: NCT00788151 Completed - Dengue Fever Clinical Trials

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

Start date: September 26, 2008
Phase: Phase 2
Study type: Interventional

The aim of the trial was to evaluate the use of a tetravalent vaccine, CYD dengue vaccine, against dengue disease. Primary Objectives: - To describe the humoral immune response to dengue before and after each vaccination with dengue vaccine in two age cohorts of children (6 to 11 years and 2 to 5 years) previously vaccinated with yellow fever (YF) vaccine. - To evaluate the safety of each vaccination with dengue vaccine in two age cohorts of children (6 to 11 years and 2 to 5 years). - To describe viremia after the first and second vaccinations with dengue vaccine in a subgroup of 130 randomized participants (100 participants in Dengue Vaccine Group and 30 participants in Control Group) in two age cohorts of children (6 to 11 years and 2 to 5 years).

NCT ID: NCT00768716 Completed - Pain Clinical Trials

Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics

Start date: December 2008
Phase: Phase 4
Study type: Interventional

Although acetaminophen is the most commonly used nonprescription drug in the USA, little is known regarding the influence of genes and race/ethnicity on acetaminophen disposition. The investigators long-term goal is to understand the causes of differences in acetaminophen disposition between people that are the result of genetic variation and ethnicity and may predispose individuals to a higher risk of acetaminophen hepatotoxicity. The aim of this particular study is to measure the rate of elimination of acetaminophen via the 3 main pathways (glucuronidation, sulfation and oxidation) in self-identified White-Americans (n=100) and African-Americans (n=100). These rates will then be correlated with selected genetic polymorphisms in genes encoding enzymes involved in acetaminophen metabolism. Two main hypotheses will be tested: 1. African-Americans eliminate acetaminophen more rapidly by glucuronidation than do White-Americans. 2. Elimination via glucuronidation, sulfation, and oxidation in subjects will be significantly correlated with the presence of polymorphisms in the UGT1A6, SULT1A1, and CYP2E1 genes, respectively.